Last reviewed · How we verify

amodiaquine+artesunate/artemether-lumefantrine

University of Ghana Medical School · Phase 3 active Small molecule

amodiaquine+artesunate/artemether-lumefantrine is a Antimalarial Small molecule drug developed by University of Ghana Medical School. It is currently in Phase 3 development for Treatment of uncomplicated malaria, Treatment of severe malaria.

Amodiaquine is a chloroquine derivative that acts as an antimalarial agent by inhibiting the parasite's heme detoxification pathway, while artesunate and artemether-lumefantrine are artemisinin-based combination therapies that rapidly kill the parasite.

Amodiaquine is a chloroquine derivative that acts as an antimalarial agent by inhibiting the parasite's heme detoxification pathway, while artesunate and artemether-lumefantrine are artemisinin-based combination therapies that rapidly kill the parasite. Used for Treatment of uncomplicated malaria, Treatment of severe malaria.

At a glance

Generic nameamodiaquine+artesunate/artemether-lumefantrine
SponsorUniversity of Ghana Medical School
Drug classAntimalarial
TargetPlasmodium heme detoxification pathway
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Amodiaquine's mechanism of action involves the inhibition of the parasite's heme detoxification pathway, which is essential for the parasite's survival. Artesunate and artemether-lumefantrine, on the other hand, rapidly kill the parasite by generating reactive oxygen species that damage the parasite's cell membrane.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about amodiaquine+artesunate/artemether-lumefantrine

What is amodiaquine+artesunate/artemether-lumefantrine?

amodiaquine+artesunate/artemether-lumefantrine is a Antimalarial drug developed by University of Ghana Medical School, indicated for Treatment of uncomplicated malaria, Treatment of severe malaria.

How does amodiaquine+artesunate/artemether-lumefantrine work?

Amodiaquine is a chloroquine derivative that acts as an antimalarial agent by inhibiting the parasite's heme detoxification pathway, while artesunate and artemether-lumefantrine are artemisinin-based combination therapies that rapidly kill the parasite.

What is amodiaquine+artesunate/artemether-lumefantrine used for?

amodiaquine+artesunate/artemether-lumefantrine is indicated for Treatment of uncomplicated malaria, Treatment of severe malaria.

Who makes amodiaquine+artesunate/artemether-lumefantrine?

amodiaquine+artesunate/artemether-lumefantrine is developed by University of Ghana Medical School (see full University of Ghana Medical School pipeline at /company/university-of-ghana-medical-school).

What drug class is amodiaquine+artesunate/artemether-lumefantrine in?

amodiaquine+artesunate/artemether-lumefantrine belongs to the Antimalarial class. See all Antimalarial drugs at /class/antimalarial.

What development phase is amodiaquine+artesunate/artemether-lumefantrine in?

amodiaquine+artesunate/artemether-lumefantrine is in Phase 3.

What are the side effects of amodiaquine+artesunate/artemether-lumefantrine?

Common side effects of amodiaquine+artesunate/artemether-lumefantrine include Nausea, Vomiting, Diarrhea, Abdominal pain, Headache.

What does amodiaquine+artesunate/artemether-lumefantrine target?

amodiaquine+artesunate/artemether-lumefantrine targets Plasmodium heme detoxification pathway and is a Antimalarial.

Related